Harrow (HROW) Assets Average (2011 - 2026)
Harrow's (HROW) quarterly Assets Average came in at $409.5 million in Q1 2026, up 8.75% year-on-year from $376.6 million in Q1 2025, and up 7.41% quarter-over-quarter from $381.3 million in Q4 2025.
Harrow (HROW) Assets Average (2011 - 2026) Analysis & Trends
Harrow's Assets Average history runs 16 years deep, the most recent figure standing at $409.5 million for Q1 2026.
- On a quarterly basis, Assets Average rose 8.75% year-over-year to $409.5 million in Q1 2026; TTM through Mar 2026 was $409.5 million, a 8.75% increase from a year earlier, with the FY2025 full-year figure at $394.2 million, up 12.45% from the prior year.
- Assets Average climbed to $409.5 million in Q1 2026 per HROW's latest filing, from $381.3 million in the prior quarter.
- Across five years, Assets Average topped out at $409.5 million in Q1 2026 and bottomed at $97.8 million in Q2 2022.
- The 5-year median for Assets Average is $301.1 million (2024), against an average of $268.5 million.
- Across the five-year window, Assets Average slipped 6.06% in 2022 and soared 158.84% in 2023, its largest moves.
- Year by year, Assets Average stood at $128.2 million in 2022, then surged by 133.35% to $299.1 million in 2023, then grew by 23.78% to $370.3 million in 2024, then rose by 2.98% to $381.3 million in 2025, then increased by 7.41% to $409.5 million in 2026.
- Per Business Quant, the three latest HROW Assets Average figures stand at $409.5 million (Q1 2026), $381.3 million (Q4 2025), and $354.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 409.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 409.51 Mn |
| Dec 31, 2025 | 381.28 Mn |
| Sep 30, 2025 | 354.05 Mn |
| Jun 30, 2025 | 354.60 Mn |
| Mar 31, 2025 | 376.57 Mn |
| Dec 31, 2024 | 370.26 Mn |
| Sep 30, 2024 | 329.08 Mn |
| Jun 30, 2024 | 301.08 Mn |
| Mar 31, 2024 | 303.85 Mn |
| Dec 31, 2023 | 299.11 Mn |
| Sep 30, 2023 | 255.03 Mn |
| Jun 30, 2023 | 220.74 Mn |
| Mar 31, 2023 | 187.44 Mn |
| Dec 31, 2022 | 128.19 Mn |
| Sep 30, 2022 | 98.53 Mn |
| Jun 30, 2022 | 97.83 Mn |
| Mar 31, 2022 | 97.96 Mn |
| Dec 31, 2021 | 100.57 Mn |
| Sep 30, 2021 | 104.88 Mn |
| Jun 30, 2021 | 81.61 Mn |